scholarly journals Erratum to: Development of a clinical risk score for pain and function following total knee arthroplasty: results from the TRIO study

2021 ◽  
Vol 5 (3) ◽  
Author(s):  
Joanna Shim ◽  
David J Mclernon ◽  
David Hamilton ◽  
Hamish A Simpson ◽  
Marcus Beasley ◽  
...  
2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Joanna Shim ◽  
David J Mclernon ◽  
David Hamilton ◽  
Hamish A Simpson ◽  
Marcus Beasley ◽  
...  

Physiotherapy ◽  
2015 ◽  
Vol 101 ◽  
pp. e532
Author(s):  
A. Alnagmoosh ◽  
A. Harmer ◽  
M. van der Esch ◽  
M. Simic ◽  
M. Fransen

Author(s):  
James L. Cook ◽  
Kylee Rucinski ◽  
Cory R. Crecelius ◽  
Suzin Cunningham ◽  
Trent M. Guess

AbstractThis prospective randomized clinical trial assessed a novel device for initial management of knee range of motion (ROM), pain, and function after total knee arthroplasty (TKA). Primary TKA patients with preoperative ROM of at least 5° to 115° were randomized to initial knee motion management: Mizzou BioJoint Flex—novel motion-assistive device with prescribed physical therapy or standard physical therapy—prescribed physical therapy. ROM, pain score, and knee injury and osteoarthritis score for joint replacement (KOOSjr) were obtained preoperatively and 2 weeks, 6 weeks, and 3 months postoperatively. Patient satisfaction for both cohorts and subjective assessments of the MBF device were assessed at 3 months. Readmissions, reoperations, and complications were assessed through 1 year. Nineteen patients were randomized to each cohort, with no significant preoperative differences in demographics, pain score, KOOSjr score, or ROM. Six SPT (31.6%) and 3 MBF (15.8%) patients failed to regain preoperative ROM (p = 0.044). One SPT (5.3%) and eight MBF (42%) patients exceeded 125° ROM (p = 0.019) by 3 months. Total ROM (p = 0.039), pain (p = 0.0068), and function (p = 0.0027) were significantly better for MBF at 3 months. MBF patients reported significantly higher satisfaction (mean, 9.4 ± 1.1 vs. 8.0 ± 1.8, respectively; p = 0.0084). One patient in each group underwent manipulation under anesthesia. No other readmissions, reoperations, or complications were reported. A novel durable medical equipment device can provide a safe and effective patient-controlled method for initial management of knee ROM, pain, and function after primary TKA with potential clinically meaningful advantages over physical therapy alone. In conjunction with physical therapy, management with this novel knee flexion device more effectively restored knee ROM and early patient function when compared with therapy alone and was associated with higher proportions of patients regaining minimum (115°) and desired (125°) levels of knee ROM and clinically meaningful differences in pain scores, knee function, and patient satisfaction. This is a Level 1, prospective trial study.


2016 ◽  
Vol 31 (11) ◽  
pp. 2402-2407.e2 ◽  
Author(s):  
Uyen-Sa D.T. Nguyen ◽  
David C. Ayers ◽  
Wenjun Li ◽  
Leslie R. Harrold ◽  
Patricia D. Franklin

2021 ◽  
Vol 4 (6) ◽  
pp. e2113977
Author(s):  
Ahmed K. Emara ◽  
Daniel Santana ◽  
Daniel Grits ◽  
Alison K. Klika ◽  
Viktor E. Krebs ◽  
...  

2021 ◽  
Author(s):  
Ziyang Dong ◽  
Yang Li ◽  
Liyuan Tao ◽  
Hua Tian

Abstract Background:Tourniquet is currently widely used in total knee arthroplasty to reduce intraoperative blood loss. Academic view of tourniquet application in TKA is now in dispute. Some scholars argue that tourniquet may cause quadriceps injury and bring extra side effects so they oppose the application of tourniquet. Others find that tourniquet application has no significant adverse impact on TKA patients. Regarding its advantages in reducing intraoperative blood loss, they advocate regular application of tourniquet in TKA. Quadriceps injury is considered the main cause of tourniquet side effects. There are now many high-quality trials about tourniquet application in TKA but few of them concentrate on quadriceps morphology and function.Methods:A prospective, single blind, randomized controlled trail will be adopted. The target sample is 130. Patients who meet the eligibility criteria will be randomly allocated to tourniquet group and non-tourniquet group. Primary outcomes are thickness, stiffness and function of quadriceps, which will be evaluated by ultrasound and rehabilitation tests. Secondary outcomes consist of circumference of thigh, VAS score, opioid consumption, knee function score, postoperative satisfaction score, operation time, intraoperative blood loss, perioperative blood loss, blood transfusion rate, D-Dimer, C-reactive protein, and complications. Discussion:This proposed study will contribute to improve evidence of tourniquet application in total knee arthroplasty. This will be a high-quality single blind randomized controlled trial with sufficient sample size and strict study design. It will investigate the effects of tourniquet application especially on the morphology and function of quadriceps in patients undergoing total knee arthroplasty and offer advice for tourniquet application in clinical practice.Trial registration:Chinese clinical trial registry, ChiCTR2000035097. Registered 31 July 2020, http://www.chictr.org.cn/showproj.aspx?proj=57093


Pain ◽  
2011 ◽  
Vol 152 (10) ◽  
pp. 2287-2293 ◽  
Author(s):  
Michael Sullivan ◽  
Michael Tanzer ◽  
Gerald Reardon ◽  
David Amirault ◽  
Michael Dunbar ◽  
...  

2018 ◽  
Vol 33 (12) ◽  
pp. 3678-3684 ◽  
Author(s):  
Stephen M. Howell ◽  
Trevor J. Shelton ◽  
Maury L. Hull

Sign in / Sign up

Export Citation Format

Share Document